Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Glecaprevir/pibrentasvir Can Reduce HCV Tx Duration

Hepatol Int; ePub 2018 May 29; Abutaleb, et al

Glecaprevir/pibrentasvir (GLE/PIB) is a fixed-dose combination therapy approved for hepatitis C virus (HCV) that has expanded reach, reduced cost, and in certain patient populations, reduced HCV treatment duration, according to a recent review. The authors concluded:

  • GLE/PIB is effective across all genotypes.
  • GLE/PIB has been shown to be effective in HIV-infected patients, patients with chronic kidney disease (CKD), and Child-Pugh A-compensated cirrhosis.
  • GLE/PIB is also effective for a shortened duration of 8 weeks in treatment-naïve non-cirrhotic patients.

Citation:

Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. [Published online ahead of print May 29, 2018]. Hepatol Int. doi:10.1007/s12072-018-9873-y.